Zynerba Pharmaceuticals focuses on developing pharmaceutically-produced transdermal cannabinoid therapies, specifically targeting rare neuropsychiatric disorders such as Fragile X syndrome (FXS) and chromosome 22q11.2 deletion syndrome (22q). Their primary product candidate, Zygel (ZYN002), is a cannabidiol gel designed for transdermal delivery to treat behavioral symptoms associated with these conditions. Zygel is formulated to enhance the bioavailability of cannabidiol by bypassing the gastrointestinal tract and liver metabolism.
Zynerba operates within the pharmaceutical industry, concentrating on orphan neuropsychiatric disorders. The company generates revenue primarily through research grants and payments for research services, as it has not yet achieved commercial product revenue. Its main client base includes patients with high unmet medical needs for whom Zygel is being developed. The company's operational structure includes partnerships with contract manufacturers across the U.S., Canada, the U.K., and Australia for producing active pharmaceutical ingredients and drug products.
Key factors impacting Zynerba's business performance include the successful development and regulatory approval of Zygel, competition from other pharmaceutical firms, and the ability to secure favorable reimbursement from third-party payers. The company's financial health is also affected by its significant research and development expenses, as well as its accumulated operating losses.